382 related articles for article (PubMed ID: 32518943)
1. How I treat relapsed or refractory AML.
DeWolf S; Tallman MS
Blood; 2020 Aug; 136(9):1023-1032. PubMed ID: 32518943
[TBL] [Abstract][Full Text] [Related]
2. How I diagnose and treat NPM1-mutated AML.
Falini B; Brunetti L; Martelli MP
Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
[TBL] [Abstract][Full Text] [Related]
3. 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.
Ivanoff S; Gruson B; Chantepie SP; Lemasle E; Merlusca L; Harrivel V; Charbonnier A; Votte P; Royer B; Marolleau JP
Am J Hematol; 2013 Jul; 88(7):601-5. PubMed ID: 23619977
[TBL] [Abstract][Full Text] [Related]
4. How I treat refractory and early relapsed acute myeloid leukemia.
Thol F; Schlenk RF; Heuser M; Ganser A
Blood; 2015 Jul; 126(3):319-27. PubMed ID: 25852056
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
7. Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.
Ye P; Pei R; Jin J; Sun J; Li K; Cao J; Zhou D; Lu Y
Ann Hematol; 2019 Sep; 98(9):2073-2080. PubMed ID: 31201514
[TBL] [Abstract][Full Text] [Related]
8. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P; Vachhani P; Cortes JE
Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
[TBL] [Abstract][Full Text] [Related]
10. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation.
Xuan L; Wang Y; Chen J; Jiang E; Gao L; Wu B; Deng L; Liang X; Huang F; Fan Z; Tang X; Sun J; Zhang X; Han M; Wu D; Huang X; Liu Q
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1674-1681. PubMed ID: 31009704
[TBL] [Abstract][Full Text] [Related]
12. Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.
Montesinos P; Bergua J; Infante J; Esteve J; Guimaraes JE; Sierra J; Sanz MÁ
Ann Hematol; 2019 Nov; 98(11):2467-2483. PubMed ID: 31667544
[TBL] [Abstract][Full Text] [Related]
13. The changing landscape for patients with relapsed/refractory acute myeloid leukaemia.
Isidori A; Ferrara F
Curr Opin Oncol; 2021 Nov; 33(6):635-641. PubMed ID: 34474436
[TBL] [Abstract][Full Text] [Related]
14. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
15. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
16. Treatment for relapsed acute myeloid leukemia: what is new?
Ofran Y; Rowe JM
Curr Opin Hematol; 2012 Mar; 19(2):89-94. PubMed ID: 22227525
[TBL] [Abstract][Full Text] [Related]
17. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
[TBL] [Abstract][Full Text] [Related]
18. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
19. Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.
Decroocq J; Itzykson R; Vigouroux S; Michallet M; Yakoub-Agha I; Huynh A; Beckerich F; Suarez F; Chevallier P; Nguyen-Quoc S; Ledoux MP; Clement L; Hicheri Y; Guillerm G; Cornillon J; Contentin N; Carre M; Maillard N; Mercier M; Mohty M; Beguin Y; Bourhis JH; Charbonnier A; Dauriac C; Bay JO; Blaise D; Deconinck E; Jubert C; Raus N; Peffault de Latour R; Dhedin N
Am J Hematol; 2018 Mar; 93(3):416-423. PubMed ID: 29226497
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
Daver N; Cortes J; Kantarjian H; Ravandi F
Expert Rev Hematol; 2016 May; 9(5):433-45. PubMed ID: 26910051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]